DESCRIPTION (provided by applicant): Progressive supranuclear palsy (PSP) is a rapidly progressive neurodegenerative disorder with clinicopathologic heterogeneity and without any therapies. Genetic studies can be instrumental in the identification of the molecular pathophysiology underlying PSP risk and its heterogeneity, which may enable discovery of therapeutic targets. Until recently, H1 haplotype of MAPT, encoding tau, was the strongest genetic risk factor for PSP. A new PSP genome-wide association study (GWAS) identified six additional loci. The effective translation of these findings to therapy requires identification of he disease gene, the functional variants and their mechanism of action. These goals cannot be achieved by the disease GWAS alone and require alternative, powerful and mechanistic approaches. The current proposal aims to close this knowledge gap by joint analysis of the whole transcriptome and quantitative neuropathology measures in a well- characterized autopsied PSP cohort with existing GWAS data. Our long-term goal is to uncover the pathophysiology of PSP and the molecular substrates of its subtypes that will ultimately lead to drug discoveries. Given the clinicopathological overlap between PSP and other tauopathies, our proposal is expected to impact a wide range of neurodegenerative disorders and generate novel therapeutic avenues. Our central hypothesis, is that many PSP variants confer risk by regulating brain gene expression. Further, differential transcriptional regulation may underlie the heterogeneity in PSP. Our preliminary data identified brain transcript associations for some of the top PSP GWAS variants supporting our hypothesis. In our Brain Bank, we have access to nearly 500 brain samples from autopsied PSP subjects with existing GWAS, ~400 of which have typical and ~100 with atypical clinicopathology. All subjects have clinical data and detailed quantitative neuropathology measures. Our objective is to obtain brain transcriptome measurements in this unique cohort, which will be analyzed jointly with quantitative neuropathology measures to identify functional variants underlying PSP risk, its clinicopathological heterogeneity and to discover the mechanism of action of these variants. The expected outcomes of our specific aims are: 1) To identify a) genetic variants that influence gene expression in PSP brains, b) transcript level differences between subtypes of PSP that are not simply due to aging; 2) To discover a) genetic factors that influence both neuropathology and gene expression in PSP; b) transcripts that correlate with neuropathology; 3) To uncover the mechanism of transcriptional regulation in PSP by a) next-generation RNA sequencing of 200 select PSP brain samples; b) translational in- vitro studies. Results from all aims will be compared with the PSP disease GWAS. The overall knowledge will nominate genes and their transcriptional changes as novel disease mechanisms in PSP. These molecular mechanisms will constitute modifiable drug targets, which will impact PSP and other related neurodegenerative diseases.
|Effective start/end date||7/15/13 → 9/30/18|
- National Institute of Neurological Disorders and Stroke: $1,786,547.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.